Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Stabilization of carotid artery plaques by pharmacologic intervention is a promising strategy for the prevention of ischemic stroke . In this study , we examined the effect of 12 months of statin therapy on carotid plaque echogenicity . This study included 81 hypercholesterolemic patients with carotid atherosclerotic plaques . Echogenicity of the largest plaque in each patient was evaluated by ultrasound with integrated backscatter analysis . All patients underwent dietary modification . Forty patients were treated with simvastatin ( 10 mg/day , n = 24 ) or atorvastatin ( 5 mg/day , n = 16 ) according to the choice by each attending physician . Carotid plaques were monitored by measuring plaque thickness and echogenicity during a 12-month follow-up period . Levels of serum high-sensitivity CRP ( hs-CRP ) , interleukin (IL)-6 and IL-18 were determined in all patients . Total cholesterol , triglyceride , hs-CRP and IL-18 were significantly decreased after 12 months of statin therapy . The change in IL-6 level was not significant . Significant increases in echogenicity of carotid plaques and decreases in plaque thickness were noted after statin therapy . In the 41 patients without statin therapy  , carotid plaque echogenicity , plaque thickness and serum levels of inflammatory markers were not significantly altered . Our results suggest that statin therapy in hypercholesterolemic patients for 12 months increases carotid plaque echogenicity and decreases plaque thickness , in addition to lowering serum levels of lipids and inflammatory markers
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .